Agilent is a global leader in life science, diagnostics and analytical laboratory technologies.

Agilent Technologies Inc. is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help customers bring science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions.

As a CDMO, Agilent supports several commercial oligonucleotide therapeutics programs. In two cGMP facilities in Colorado, US, Agilent produces siRNA, antisense, aptamers, sgRNA, and other oligonucleotides. In 2023 Agilent announced a $725 million investment to expand manufacturing capacity that will allow us to take on more programs, increase batch sizes, and address our partners’ needs more quickly.

For the pharmaceutical and biopharmaceutical industries, Agilent provides end-to-end workflows from research and drug discovery, to development, manufacturing, and quality control. We strive to provide reliable answers to help overcome analytical challenges and optimize the productivity needs of labs. Complete solutions to help get products to market faster.

Leveraging more than 50 years of expertise, we create instruments, software, services and solutions that provide trusted answers to our customers’ most critical questions. We are passionate about helping them solve their most ambitious scientific challenges, increase laboratory performance, and advance the quality of life.